These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29957886)

  • 21. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
    Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
    Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I; Selph S
    Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
    Jensterle M; Kravos NA; Goričar K; Janez A
    BMC Endocr Disord; 2017 Jan; 17(1):5. PubMed ID: 28143456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.
    Li CJ; Yu Q; Yu P; Yu TL; Zhang QM; Lu S; Yu DM
    Cardiovasc Diabetol; 2014 Feb; 13():36. PubMed ID: 24498905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
    Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
    Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
    Matikainen N; Söderlund S; Björnson E; Pietiläinen K; Hakkarainen A; Lundbom N; Taskinen MR; Borén J
    Diabetes Obes Metab; 2019 Jan; 21(1):84-94. PubMed ID: 30073766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
    J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
    Belcher G; Lambert C; Edwards G; Urquhart R; Matthews DR
    Diabetes Res Clin Pract; 2005 Oct; 70(1):53-62. PubMed ID: 16002175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of metformin and alogliptin on body composition in people with type 2 diabetes.
    Takeshita Y; Kita Y; Kato KI; Kanamori T; Misu H; Kaneko S; Takamura T
    J Diabetes Investig; 2019 May; 10(3):723-730. PubMed ID: 30156056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.
    Ma Z; Chen R; Liu Y; Yu P; Chen L
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):933-9. PubMed ID: 26365337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
    Belcher G; Schernthaner G
    Diabet Med; 2005 Aug; 22(8):973-9. PubMed ID: 16026360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.
    Rizvi AA; Patti AM; Giglio RV; Nikolic D; Amato A; Al-Busaidi N; Al-Rasadi K; Soresi M; Banach M; Montalto G; Rizzo M
    Expert Opin Biol Ther; 2015; 15(10):1391-7. PubMed ID: 26195184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
    Shestakova MV; Suhareva OIu; Chernova TO; Shmushkovich IA; Aleksandrov AA; Il'in AV; Dedov II
    Ter Arkh; 2013; 85(8):49-55. PubMed ID: 24137964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Liu L; Yan H; Xia M; Zhao L; Lv M; Zhao N; Rao S; Yao X; Wu W; Pan B; Bian H; Gao X
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3292. PubMed ID: 31955491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S; Collober-Maugeais C; Pecher E; Cressier F
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.